Artificial intelligence is generating enormous interest in reproductive medicine — and for understandable reasons. The idea that machine learning could improve embryo selection, personalize stimulation protocols, or predict outcomes more accurately than conventional methods is genuinely compelling. Understanding what AI can and cannot currently do, however, requires setting aside the marketing and looking at the evidence.
Where AI is being applied in fertility treatment
The applications under active development or already in clinical use span several areas of the IVF process:
- Forecasting ovarian response and predicting treatment outcomes based on patient-specific data
- Customizing hormone dosage for stimulation protocols using predictive algorithms
- Automated follicle tracking during monitoring visits, reducing variability between sonographers
- Enhanced sperm evaluation based on morphological parameters assessed by image analysis
- Embryo quality prediction through continuous time-lapse image analysis
- Optimizing donor-recipient matching based on compatibility algorithms
These are not speculative applications — commercial products exist in each of these categories. The question is not whether AI is being used, but whether it is being used wisely.
Fertility prediction tools
Prediction tools fall into two broad categories. Population-based tools, such as those offered by the CDC and SART in the United States, use aggregate registry data to estimate success rates for patients with similar characteristics. Subscription-based platforms offer more individualized estimates using proprietary algorithms. Both can be useful as starting points for understanding what might be possible — but both carry important limitations. Clinical judgment remains essential for interpreting AI-generated predictions in the context of a specific patient’s full history, values, and circumstances. A percentage on a screen does not capture everything that matters in a fertility consultation.
Current limitations
The limitations of AI in reproductive medicine are real and deserve candid acknowledgment. Training data quality directly affects prediction accuracy — if a model is trained on data from a particular population or clinical setting, its outputs may not generalize to different contexts. Most tools function only within the specific clinical environment where they were developed and validated. Perhaps most critically, as multiple systematic reviews have concluded, most AI-based fertility tools are supported by low or very low levels of clinical evidence.
There is also a risk of patient confusion. When algorithmic reports are handed to patients without adequate physician interpretation, the numbers can create false certainty — or false despair — that a proper clinical conversation would have avoided. AI outputs require contextualization, not just delivery.
Evidence-based adoption
The promise of AI in reproductive medicine is real, and the field will almost certainly continue to advance. But commercial pressure — the incentive to sell a new technology — often drives implementation faster than the evidence base can support. Clinics that adopt every new AI tool without demanding rigorous validation are not offering patients better care; they are offering patients novelty at a premium.
The responsible path is cautious, rigorous adoption — evaluating each application based on its clinical evidence, not its marketing claims, and being transparent with patients about what is established versus what remains experimental.
“AI can process patterns in data that humans can’t see. But it can’t replace the judgment, communication, and individualized care that good medicine requires.”
